Comparing minimally invasive surgeries for stomach cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the short-term appetite and nutritional outcomes of patients undergoing minimally invasive proximal gastrectomy (MIPG) versus those undergoing total gastrectomy (MITG) for non-metastatic gastric and gastroesophageal junction adenocarcinoma. The primary objective is to determine if MIPG leads to better postoperative appetite levels, which may improve nutritional status and body weight maintenance. Patient-reported outcomes will be assessed using the MD Anderson Symptom Inventory Gastrointestinal Cancer Module and additional questionnaires to evaluate quality of life and correlate appetite levels with fasting ghrelin levels. The study will also investigate safety and oncological outcomes associated with both surgical approaches.

Why it matters

Who can join: the full rules

Inclusion:

1. Able to speak and read English, Spanish, Japanese or Korean
2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
3. Age ≥ 18

Exclusion:

1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
2. Participants with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent
3. Participants deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Keio University School of Medicine
  Tokyo, Japan Recruiting
• Yonsei University College of Medicine
  Soeul, South Korea Recruiting
• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Active not recruiting

Study contacts

• Principal investigator: Naruhiko Ikoma, MD — M.D. Anderson Cancer Center
• Study coordinator: Naruhiko Ikoma, MD
• Email: nikoma@mdanderson.org
• Phone: (832) 729-2675

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• First-in-human dose study of DA-3501 for CLDN18.2-positive stomach, GEJ cancer, and pancreatic cancer

  A first-in-human study tests DA-3501 in adults with CLDN18.2-positive advanced stomach/GEJ cancer or pancreatic cancer to find a safe, effective dose.

  Recruiting at 3 sites Phase 1 Dong-A ST Co., Ltd. · Seongnam, Bundang and 2 other locations · NCT07481357

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• High bile-binding foods to reduce bile acids in the upper digestive tract

  This test will see if different gastrostomy tube feeds—a standard amino acid formula, a low bile‑binding blended feed, or a high bile‑binding blended feed—lower bile acid levels in the stomach and saliva of people who get most of their nutrition through a gastrostomy.

  Recruiting Phase 4 Boston Children's Hospital · Boston, Massachusetts · NCT07303738

• EOI block to reduce pain during pediatric laparoscopic gastrostomy

  This trial will test whether an ultrasound-guided external oblique intercostal (EOI) block with ropivacaine reduces pain during and after laparoscopic gastrostomy in children aged 3 to 18.

  Recruiting Seoul National University Hospital · Seoul · NCT07119346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.